Navigation Links
UT Southwestern researchers find drug-coated stents less risky for heart bypass patients
Date:1/21/2009

dure with bare-metal stents.

Researchers found that 51 percent of patients with the bare-metal stent had re-narrowing of the vein graft over several months compared with 9 percent of the drug-eluting stent group. In addition, 28 percent of patients who had a bare-metal stent required another procedure to treat the same blockage, while only 5 percent of patients who had the drug-eluting stent did.

Some previous studies have indicated that patients receiving drug-eluting stents in saphenous vein grafts may not reduce the risk of re-narrowing and may be associated with increased risk of death, Dr. Brilakis said.

"Our findings suggest that drug-eluting stents are a better choice than bare-metal stents for this type of procedure," he said. "Patients receiving paclitaxel-eluting stents in our study were significantly less likely to have recurrence of their graft blockage and to require repeat procedures. The rates of death were similar in both study groups, although our study was not designed to detect differences in mortality."

The researchers now hope to repeat the study in an expanded group of patients, which would provide important data to determine definitively the efficacy and safety of each kind of stent.


'/>"/>

Contact: Katherine Morales
katherine.morales@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. UT Southwestern University Hospitals transplant program recognized for increasing organ donor rates
2. Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert
3. Interferon needed for cells to remember how to defeat a virus, UT Southwestern researchers report
4. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
5. Cancer requires support from immune system to develop, UT Southwestern researchers report
6. Vaginal/Caesarean combo delivery of twins safe, UT Southwestern-led research finds
7. Steroids aid recovery from pneumonia, UT Southwestern researchers say
8. Superbug breast infections controllable in nursing mothers, UT Southwestern researchers find
9. UT Southwestern scientists discover leptin can also aid type 1 diabetics
10. Tiny molecule helps control blood-vessel development, UT Southwestern researchers find
11. UT Southwestern launches study of surgical option for treating diabetic and other neuropathies
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 1Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 1Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 3Nostrils Compete to Relay Key Fragrance 54963 1Nostrils Compete to Relay Key Fragrance 54963 2